Q2 2026 Revenue up 241% year over year to $458K · 505¢ of every $1 of revenue lost · operating margin -554.3%
Medicinova made $458K in Q2 2026 (+241% Y/Y). Operating margin -554.3%, net loss $2.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Revenue$458K
Year over year+241%
Operating margin-554.3%
Net earnings−$2.3M
Operating cash flow−$1.9M
Drawing the Sankey…
Open the interactive Sankey →click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $458K in Q2 2026, up 241% year over year and up 145% from the previous quarter.
Operating costs exceeded revenue by $2.5M, an operating margin of -554.3%. Total costs fell 20% while revenue rose 241%. The fastest-growing cost line was General & admin (+27%). The quarter ended with a net loss of $2.3M, narrower than the previous quarter's $2.6M loss.
Operating cash flow was −$1.9M. Non-cash charges added back $5K of depreciation and amortization and $177K of share-based compensation. Working capital and other items added $212K.
Quarterly history
Quarter
Form
Filed
Revenue
Y/Y
Op. margin
Net earnings
Op. cash flow
Q2 2026
10-Q
Aug 13, 2026
$458K
+241%
-554.3%
−$2.3M
−$1.9M
Q1 2026
10-Q
May 14, 2026
$187K
—
n/m
−$2.6M
−$3.5M
Q4 2025
10-K
Mar 10, 2026
$152K
—
n/m
−$2.8M
−$2.0M
Q3 2025
10-Q
Nov 12, 2025
$123K
—
n/m
−$3.1M
−$1.7M
Q2 2025
10-Q
Aug 14, 2025
$135K
—
n/m
−$3.3M
−$2.3M
Charts
Latest (Q2 2026): Y/Y +241%, Q/Q +145%.From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.Latest (Q2 2026): Net income −$2.3M, Operating cash flow −$1.9M.+10.5% since FY2020: more shares outstanding (issuance, stock pay).Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Medicinova against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +241% against the peers' median +10%. Operating margin: -554.3% against the peers' median 20.4%.